Evaluation of d-amphetamine effects on the binding of dopamine D-2 receptor radioligand, 18F-fallypride in nonhuman primates using positron emission tomography

Synapse

Volumn 27, Issue 1, 1997, Pages 1-13

  Mukherjee, Jogeshwar ^a   Yang, Zhi Ying ^a   Lew, Robert ^b   Brown, Terry ^a   Kronmal, Shara ^a   Cooper, Malcolm D ^a   Seiden, Lewis S ^b  

^a Franklin McLean Memorial Research Institute   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

18F fallypride; Amphetamine; Dopamine D2 receptors; Monkey PET

Indexed keywords

DEXAMPHETAMINE; DOPAMINE 2 RECEPTOR; RACLOPRIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; COMPETITIVE INHIBITION; CONTROLLED STUDY; DISSOCIATION CONSTANT; DOPAMINERGIC TRANSMISSION; DRUG EFFICACY; DRUG RECEPTOR BINDING; LIGAND BINDING; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; POSTSYNAPTIC MEMBRANE; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY; STRIATE CORTEX;

ANIMALS; BRAIN; DEXTROAMPHETAMINE; DOPAMINE; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HALOPERIDOL; MACACA; MALE; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D2; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0030799494     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2396(199709)27:1<1::AID-SYN1>3.0.CO;2-9     Document Type: Article

References (39)

1. Al-Tikriti, M.S., Baldwin, R.M., Zea-Ponce, Y., Sybirska, E., Zoghbi, S.S., Laruelle, M., Malíson, R.T., Kung, H.F., Kessler, R.M., Charney, D.S., Hoffer, P.B., and Innis, R.B. (1994) Comparison of three high affinity SPECT radiotracers for the dopamine D-2 receptor. Nucl. Med. Biol., 21:179-188.
2. Berglund, M., and Risberg, J. (1980) Regional cerebral blood flow in a case of amphetamine intoxication. Psychopharmacology, 70:219-221.
3. Church, H., Justice, J.B.J., and Neill, D.B. (1987) Detecting behaviorally relevant changes in extracellular dopamine with microdialysis. Brain Res., 412:397-399.
4. DeJesus, O.T., Van Moffaert, G.J.C., Dinerstein, R.J., and Friedman, A.M. (1986) Exogenous L-DOPA alters spiroperidol binding in vivo in the mouse striatum. Life Sci., 39:341-349.
5. Dewey, S.L., Logan, J., Wolf, A.P., Brodie, J.D., Angrist, B., Fowler, J.S., and Volkow, N.D. (1991) Amphetamine induced decreases in [F-18]N-methylspiroperidol binding in the baboon brain by PET. Synapse, 7:324-327.
6. Dewey, S.L., Smith, G.S., Logan, J., Brodie, J.D., Yu, D.W., Ferrieri, R.A., King, P.T., Macgregor, R., Martin, T.P., and Wolf, A.P. (1992) GABAergic inhibition of endogenous dopamine release measured in vivo with C-11 raclopride and PET. J. Neurosci., 12:3773-3780.
7. Dewey, S.L., Smith, G.S., Logan, J., Simkowitz, P., Brodie, J.D., Fowler, J.S., Volkow, N.D., and Wolf, A.P. (1993) Striatal binding of the PET ligand, [C-11]raclopride is altered by drugs that modify synaptic dopamine levels. Synapse. 13:350-356.
8. Farde, L., Nordstrom, A.L., Wiesel, F.A., Pauli, S., Halldin, C., and Sedvall, G. (1992) Positron emission tomography analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Arch. Gen. Psychiatry, 49:538-544.
9. Freeman, K.A., and Tallarida, R.J. (1994) A quantitative study of dopamine control in rat striatum. J. Pharmacol. Exp. Ther., 268:629-638.
10. Friedman, A.M., DeJesus, O.T., Revenaugh, J., and Dinerstein, R.J. (1984) Measurements in vivo of parameters of the dopamine system. Ann. Neurol., 15 Suppl:S66-76.
11. Gifford, A.N., Gatley, S.J., and Ashby, C.R. (1996) Endogenously released dopamine inhibits the binding of dopaminergic PET and SPECT ligands in superfused rat striatal slices. Synapse, 22:232-238.
12. Hall, H., Hogberg, T., Halldin, C., Kohler, C., Strom, P., Ross, S.B., Larsson, S.A., and Farde, L. (1991) NCQ 298, a new selective iodinated salicylamide ligand for the labeling of dopamine D2 receptors. Psychopharmacology, 103:6-18.
13. Heeringa, M.J., and Abercrombie, E.D. (1995) Biochemistry of somatodendritic dopamine release in substantia nigra: An in vivo comparison with striatal dopamine release. J. Neurochem., 65:192-200.
14. Hume, S.P., Myers, R., Bloomfield, P.M., Opacka-Juffry, J., Cremer, J.E., Ahier, R.G., Luthra, S.K., Brooks, D.J. and Lammertsma, A.A. (1992) Quantitation of carbon-11 labeled raclopride in rat striatum using positron emission tomography. Synapse, 12:47-54.
15. Innis, R.B., Malison, R.T., Al-Tikriti, M., Hoffer, P.B., Sybirska, E.H., Seibyl, J.P., Zoghbi, S.S., Baldwin, R.M., Laruelle, M., Smith, E.O., Charney, D.S., Heninger, G., Elsworth, J.D., and Roth, R.H. (1992) Amphetamine stimulated dopamine release competes in vivo for 123I-IBZM binding to the D-2 receptor in non-human primates. Synapse, 10:177-184.
16. 125I]Epidepride: In vivo studies in rhesus monkey brain and comparison with in vitro pharmacokinetics in rat brain. Life Sci., 53:241-250.
17. 3H-raclopride. Biochem. Pharmacol., 34:2251-2259.
18. Kuczenski, R., and Segal, D. (1989) Concomitant characterization of behavioral and striatal neurotransmitter response to amphetamine using in vivo microdialysis. J. Neurosci., 9:2051-2086.
19. Kuczenski, R., Segal, D., and Aizenstein, M.L. (1991) Amphetamine, cocaine, and fencamfamine: Relationship between locomotor and stereotypy response profiles and caudate and accumbens dopamine dynamics. J. Neurosci., 11:2703-2712.
20. Laruelle, M., Abi-Dargham, A., van Dyck, C.H., Rosenblatt, W., Zea-Ponce, Y., Zoghbi, S.S., Baldwin, R.M., Charney, D.S., Hoffer, P.B., Kung, H.F., and Innis, R.B. (1995) SPECT imaging of striatal dopamine release after amphetamine challenge. J. Nucl. Med., 36:1182-1190.
21. Logan, J., Dewey, S.L., Wolf, A.P., Fowler, J., Brodie, J.D., Angrist, B., Volkow, N.D., and Gatley, S.J. (1991) Effects of endogenous dopamine on measures of [F-18]NMSP binding in the basal ganglia: Comparison of simulations and experimental results from PET studies in baboons. Synapse, 9:195-207.
22. Mach, R.H., Ehrenkaufer, R.L.E., Nader, M.A., Line, S.W., Smith, C.R., Hubbard, C., Kung, M-P., Kung, H.F., Luedtke, R.R., and Morton, T.E. (1995) Validation studies of [18F]fluoroclebopride ([18F]FCP): A benzamide analogue that binds reversibly to dopamine D2 receptors. J. Label. Compds. Radiopharm., 37:21-23.
23. McCulloch, J., Deshmukh, V.D., and Harper, A.M. (1977) Indirect sympathomimetics and cerebral blood flow and metabolism. Acta Neurolg. Scand., 864:94-95.
24. Moghaddam, B., Berridge, C.W., Goldman-Rakic, P.S., Bunney, B.S., and Roth, R.H. (1993) In vivo assessment of basal and drug-induced dopamine release in cortical and subcortical regions of the anesthetized primate. J. Neurosci., 13:215-222.
25. Mukherjee, J., Yang, Z.-Y., Das, M.K., and Brown, T. (1995a) Fluorinated benzamide neuroleptics-3. Development of (S)-N-[(1-allyl-2-pyrrolidinyl)methyl]-5-(3-[F-18]fluoropropyl)-2,3-dimethoxy- benzamide as an improved dopamine D-2 receptor tracer. Nucl. Med. Biol., 22:283-296.
26. Mukherjee, J., Yang, Z.-Y., Brown, T., Jiang, M., Kapp, O., Chen, C.-T., and Cooper, M. (1995b) Potential anomalies of dopamine D-2 receptor: Challenges for non-invasive imaging studies by positron emission tomography. Med. Chem. Res., 5:174-192.
27. 18F-Desmethoxyfallypride: A fluorine-18 labeled radiotracer with properties similar to carbon-11 raclopride for PET imaging studies of dopamine D-2 receptors. Life Sci., 59:669-678.
28. Munson, P.J., and Rodbard, D. (1980) LIGAND: A versatile approach for the characterisation of ligand binding systems. Anal. Biochem., 107:220-239.
29. 3H-raclopride in the mouse brain in vivo. Archives Pharmacol., 340:6-12.
30. Seeman, P., Watanabe, M., Grigoriadis, D., Tedesco, J.L., George, S.R., Svensson, U., Nilsson, J.L.G., and Neumeyer, J.L. (1986) Dopamine D-2 receptor binding sites for agonists: A tetrahedral model. Mol. Pharmacol. 28:391-399.
31. Seeman, P., Guan, H.-C., and Niznik, H.B. (1989) Endogenous dopamine lowers the dopamine D-2 receptor density as measured by [H-3]raclopride: Implications for positron emission tomography of the human brain. Synapse, 3:96-97.
32. Seeman, P., Niznik, H.B., and Guan, H.-C. (1990) Evaluation of dopamine D-2 receptors in schizophrenia is underestimated by radioactive raclopride. Arch. Gen. Psych., 47:1170-1172.
33. Seiden, L.S., Sabol, K.E., and Ricaurte, G.A. (1993) Amphetamine: Effects on catecholamine systems and behavior. Ann. Rev. Pharmacol. Toxicol., 32:639-677.
34. Sharp, T., Zetterstorm, T., and Ungerstedt, U. (1986) An in vivo study of dopamine release and metabolism in rat brain regions using intracerebral dialysis. J. Neurochem., 47:113-122.
35. Ter-Pogossian, M.M., Ficke, D.C., Hood, J.T., Yamamoto, M., and Mullani, N.A. (1982) PETT VI: A positron emission tomograph utilizing cesium fluoride scintillation detectors. J. Comput. Assist. Tomogr., 6:125-133.
36. Volkow, N.D., Wang, G.-J., Fowler, J.S., Logan, J., Schlyer, D.J., Hitzemann, R., Lieberman, J., Angrist, B., Pappas, N., MacGregor, R., Burr, G., Cooper, T., and Wolf, A.P. (1994) Imaging endogenous dopamine competition with [11C]raclopride in the human brain. Synapse, 16:255-262.
37. Volkow, N.D., Fowler, J.S., Gatley, S.J., Logan, J., Wang, G.J., Ding, Y-S., and Dewey, S.L. (1996) PET evaluation of the dopamine system of the human brain. J. Nucl. Med., 37:1242-1256.
38. Young, L.T., Wong, D.F., Goldman, S., Minkin, E., Chen, C., Matsumura, K., Scheffel, U., and Wagner, H.N., Jr. (1991) Effects of endogenous dopamine on kinetics of [3H]N-methylspiperone and [3H]raclopride binding in the brain. Synapse, 9:188-194.
39. Zetterstorm, T., Sharp, T., Marsden, C.A., and Ungerstedt, U. (1983) In vivo measurement of dopamine and its metabolites by intracerebral dialysis: Changes after d-amphetamine. J. Neurochem., 41: 1769-1773.